Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Robbins

Showing results (261-270 of 331) with videos related to

Pageof 34
Sort By:
Open Forum Infectious Diseases|April 18, 2015
Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group ProtocolsCarrie B Moore, Anurag Verma, Sarah Pendergrass, et al.
Cell Death and Differentiation|July 3, 2020
MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3<sup>+</sup> regulatory T cellsCharis E Teh, Alissa K Robbins, Darren C Henstridge, et al.
Human Reproduction (Oxford, England)|April 5, 2018
Subphenotype meta-analysis of testicular cancer genome-wide association study data suggests a role for RBFOX family genes in cryptorchidism susceptibilityYanping Wang, Dione R Gray, Alan K Robbins, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityGeorge L Melikian, Soo-Yon Rhee, Jonathan Taylor, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2001
The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individualsM M Addo, M Altfeld, E S Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study GroupD Schrijvers, J Johnson, U Jiminez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2006
Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group studyTodd Hulgan, Michael Hughes, Xin Sun, et al.
AIDS (London, England)|May 17, 2023
Cognitive concerns are a risk factor for mortality in people with HIV and coronavirus disease 2019Douglas R Wilcox, Emily A Rudmann, Elissa Ye, et al.
Contemporary Clinical Trials|May 2, 2021
Evaluation of an integrated treatment to address smoking cessation and anxiety/depressive symptoms among people living with HIV: Study protocol for a randomized controlled trialLorra Garey, Megan R Wirtz, Allison K Labbe, et al.
AIDS (London, England)|October 18, 2005
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosidesMichael P Dubé, Robert A Parker, Pablo Tebas, et al.
Pageof 34

Showing results (261-270 of 331) with videos related to

Sort By:
Pageof 34
Open Forum Infectious Diseases|April 18, 2015
Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group ProtocolsCarrie B Moore, Anurag Verma, Sarah Pendergrass, et al.
Cell Death and Differentiation|July 3, 2020
MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3<sup>+</sup> regulatory T cellsCharis E Teh, Alissa K Robbins, Darren C Henstridge, et al.
Human Reproduction (Oxford, England)|April 5, 2018
Subphenotype meta-analysis of testicular cancer genome-wide association study data suggests a role for RBFOX family genes in cryptorchidism susceptibilityYanping Wang, Dione R Gray, Alan K Robbins, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityGeorge L Melikian, Soo-Yon Rhee, Jonathan Taylor, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2001
The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individualsM M Addo, M Altfeld, E S Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study GroupD Schrijvers, J Johnson, U Jiminez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2006
Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group studyTodd Hulgan, Michael Hughes, Xin Sun, et al.
AIDS (London, England)|May 17, 2023
Cognitive concerns are a risk factor for mortality in people with HIV and coronavirus disease 2019Douglas R Wilcox, Emily A Rudmann, Elissa Ye, et al.
Contemporary Clinical Trials|May 2, 2021
Evaluation of an integrated treatment to address smoking cessation and anxiety/depressive symptoms among people living with HIV: Study protocol for a randomized controlled trialLorra Garey, Megan R Wirtz, Allison K Labbe, et al.
AIDS (London, England)|October 18, 2005
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosidesMichael P Dubé, Robert A Parker, Pablo Tebas, et al.
Pageof 34